Holen Sie sich die Stockscreener-App
0.00
100.00%
-5.11
Schlusskurs vom Vortag:
$5.11
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$342.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.20M
KGV:
0.00
EPS:
-1.69
Netto-Cashflow:
$57,000
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$11.55
Eliem Therapeutics Inc Stock (ELYM) Company Profile
Firmenname
Eliem Therapeutics Inc
Sektor
Branche
Telefon
877-354-3689
Adresse
2801 CENTERVILLE ROAD 1ST FLOOR, WILMINGTON
Eliem Therapeutics Inc Aktie (ELYM) Neueste Nachrichten
How To Trade (CLYM) - Stock Traders Daily
Climb Bio to present kidney disease treatment study - Investing.com India
Climb Bio to present kidney disease treatment study By Investing.com - Investing.com UK
Eliem Therapeutics Inc [ELYM] Shares Fall -0.97 % on Wednesday - Knox Daily
Eliem Therapeutics rebrands to Climb Bio, shifts focus to immune diseases - Investing.com
Eliem Therapeutics Changes Name to Climb Bio - Yahoo Finance
Eliem Therapeutics to change corporate name to Climb Bio - TipRanks
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. - The Manila Times
Healthy Upside Potential: Eliem Therapeutics Inc (ELYM) - SETE News
Monitoring Eliem Therapeutics Inc (ELYM) after recent insider movements - Knox Daily
Eliem Therapeutics Inc (ELYM) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Ratio Analysis: Unpacking Eliem Therapeutics Inc (ELYM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Stock Position Decreased by Driehaus Capital Management LLC - MarketBeat
Selling Eliem Therapeutics Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Private equity firms who have a significant stake must be disappointed along with institutions after Eliem Therapeutics, Inc.'s (NASDAQ:ELYM) market cap dropped by US$231m - Yahoo Finance
Eliem Therapeutics Inc (ELYM) can make a big difference with a little luck - SETE News
Eliem Therapeutics Inc (ELYM) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Affinity Asset Advisors LLC Takes $11.88 Million Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM) - MarketBeat
Trading (ELYM) With Integrated Risk Controls - Stock Traders Daily
500,000 Shares in Eliem Therapeutics, Inc. (NASDAQ:ELYM) Acquired by Ally Bridge Group NY LLC - MarketBeat
Eliem Therapeutics: Recent Strategic Pipeline Restructuring (NASDAQ:ELYM) - Seeking Alpha
Closing Figures: Eliem Therapeutics Inc (ELYM)’s Positive Finish at 8.43, Up 1.81 - The Dwinnex
Eliem Therapeutics Inc (ELYM)’s stock price in review: A technical analysis - US Post News
Eliem therapeutics executive sells over $9,000 in company stock By Investing.com - Investing.com Australia
Eliem therapeutics executive sells over $9,000 in company stock - Investing.com
(ELYM) Trading Signals - Stock Traders Daily
Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - GlobeNewswire
Eliem Therapeutics (NASDAQ:ELYM) Trading Up 4.6% - MarketBeat
Eliem Therapeutics Inc [ELYM] Investment Appeal on the Rise - Knox Daily
ELYM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
A Guide To The Risks Of Investing In Eliem Therapeutics Inc (ELYM) - Knox Daily
Eliem Therapeutics appoints Kaplan as COO; Rampal as SVP, Clinical Development - MSN
Eliem Therapeutics announces executive changes, refocuses on autoimmune diseases - Investing.com India
Eliem Therapeutics: Executive Changes Amid Strategic Shift - TipRanks
Eliem Therapeutics expands executive team with new COO and SVP - Investing.com
Eliem Therapeutics appoints new COO Brett Kaplan - Investing.com
Eliem Therapeutics appoints new COO Brett Kaplan By Investing.com - Investing.com UK
Eliem Therapeutics Names Brett Kaplan as New COO - TipRanks
Eliem Therapeutics Announces Additions to its Leadership Team - GlobeNewswire
Eliem Therapeutics Announces Additions to its Leadership Team - GlobeNewswire Inc.
ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q2 2024 - MSN
(ELYM) Long Term Investment Analysis - Stock Traders Daily
Eliem Therapeutics, Inc. (NASDAQ:ELYM) Short Interest Up 34.0% in July - Defense World
Analyzing Eliem Therapeutics Inc (ELYM) After Recent Trading Activity - Knox Daily
Eliem Therapeutics Reports Second Quarter Financial Results - ForexTV.com
Sciatica Treatment Industry is Expected to Reach Rapid Growth - openPR
ELYM’s 2023 Market Dance: Up 124.07% – Time to Invest? - The InvestChronicle
Daily Progress: Eliem Therapeutics Inc (ELYM) Drop -15.50, Closing at 6.05 - The Dwinnex
Recent Insider Activity Could Benefit Eliem Therapeutics Inc (ELYM) - Knox Daily
How To Trade (ELYM) - Stock Traders Daily
Where are the Opportunities in (ELYM) - Stock Traders Daily
Finanzdaten der Eliem Therapeutics Inc-Aktie (ELYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):